.png)
Pluri (Pluristem)
Placental cell therapy (PLX-R18) for acute radiation syndrome; DoD/NIAID nuclear countermeasure
Latest event found: 27 Aug 2026 · about 2 months ago
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
Pluri is shifting from a primarily platform-development biotechnology company toward commercialization through Cellav regenerative aesthetics and Ever After Foods cultivated-protein ventures, while continuing to build its cell-expansion intellectual-property base. The strategy is increasingly diversified and partnership-led, but remains dependent on external capital and execution across multiple early-stage commercial programs.
Efficiency Ratio
Resource-to-output efficiency appears moderate: the company is converting a relatively small team and approximately $14 million of available cash at December 31, 2025 into patents, regulatory progress, ventures, and partnerships, but recurring commercial revenue and scaled product execution remain limited.
Evidence Signals
Pluri announced pricing of a $3.3 million registered direct offering and concurrent private placement with a healthcare-focused institutional investor.
Pluri’s Ever After Foods subsidiary acquired Belgium-based Fishway and raised $2 million in strategic funding to expand its cultivated-protein platform.
Pluri’s Cellav subsidiary completed regulatory registration in the United Kingdom for an aesthetics product, supporting planned commercial expansion.
Over the preceding year, Alejandro Weinstein invested more than $17 million through multiple investments, including a $1.25 million advance investment in June 2026, and his ownership exceeded 30%.
Alejandro Weinstein’s ownership of Pluri exceeded 30% following cumulative investments; the available sources do not indicate that Pluri was acquired, merged, or sold in a transaction transferring control.
An entity beneficially owned by Chairman Alejandro Weinstein entered into an agreement to invest $2.5 million in Pluri at a 30% premium to the market price.
China’s National Intellectual Property Administration granted Pluri Biotech, a wholly owned subsidiary, a patent covering its three-dimensional immune-cell expansion and activation technology.
- About
- Israeli cell-therapy / biotech company (HQ Haifa, Israel — MATAM Park; Nasdaq/TASE: PLUR; formerly Pluristem Therapeutics; founded 2003; CEO Yaky Yanay). Pluri's core asset is a patented 3D cell-expansion platform that mass-produces cells consistently and at scale; the company applies it across TWO arms — regenerative medicine AND food-tech/sustainability (cultivated-meat / agtech). Its defense-relevant program is PLX-R18 (avoplacel), an off-the-shelf intramuscular placental cell therapy for hematopoietic acute radiation syndrome (H-ARS) — radiation poisoning from a nuclear/radiological accident, attack or warfare. PLX-R18 is developed under the FDA Animal Rule toward the US Strategic National Stockpile (IND cleared, Orphan Drug Designation) and is actively funded/studied by the US DoD's AFRRI/USUHS and the NIH's NIAID (a 3-year contract signed 2023, ~$4.2M; NIAID exercised its 2nd-year option in 2024); in Nov 2024 Pluri began assessing mass-production readiness amid rising nuclear-threat concerns. Animal studies showed survival rising from ~29% (control) to ~97% (treated). Important: Pluri's center of gravity is a broad cell-expansion platform (incl. food-tech), NOT a defense pure-play — it earns its defense-health place specifically on the active, government-funded PLX-R18 radiation-countermeasure program.
- Tags
- #radiation #ARS #celltherapy #placental #medicalcountermeasure #dod #niaid #nuclear #cbrn #rxbio #dualuse